Identification of JAK2 dependent transcriptional regulators in CML

Rhodes, S. , Copland, M. , Hopcroft, L. , Sayeski, P. and Wheadon, H. (2013) Identification of JAK2 dependent transcriptional regulators in CML. In: 42nd Annual Scientific Meeting of the ISEH – Society for Hematology and Stem Cells, Vienna, Austria, 22-25 Aug 2013, S47-S47.

Full text not currently available from Enlighten.

Publisher's URL: http://www.iseh.org/?2013Vienna

Abstract

Chronic myeloid leukaemia (CML) is characterised by the t(9;22)(q34;q11) chromosomal translocation which gives rise to the active tyrosine kinase fusion protein BCRABL, responsible for driving the disease from the haemopoietic stem cell through to mature myeloid cells. The JAK2 pathway is activated in CML through several mechanisms and has effects on numerous transcription factors and cell cycle regulators, making it an attractive additional target for further treatment in CML. Following bioinformatics analysis of microarray data obtained from the literature, we identified a transcriptional regulatory network downstream from JAK2 and generated a linked gene interaction map. The key genes identified control multiple cell functions which could be affected by deregulation of JAK2 signalling. Using Fluidigm technology this network was analysed in CML patient peripheral blood mononuclear cells (PBMNC) and compared to normal PB-MNC by real time PCR. Data was obtained on 29 transcriptional regulation genes, of these 45% were up-regulated including regulators of cell cycle (CDKN1B, CDK1, FOXM1), differentiation and proliferation (TFDP1, EZH2), 10% were down-regulated including regulators of apoptosis (TNFSF10), and 45% were unchanged including HSP90 and PI3K. Treatment of K562 cells using concentrations of JAK2 inhibitors based on IC50 experiments showed concentration dependent reversal in the up-regulated genes (31% for AT9283, 46% for TG101209 and 46% for ruxolitinib treated cells), and in the down-regulated genes (33% for AT9283, 67% for TG101209 and 67% for ruxolitinib treated cells). Preliminary data in CML CD34+ patient samples treated with single agent nilotinib and ruxolitinib or combination followed a similar pattern, but requires further validation. Overall this study has identified an important transcriptional network downstream of activated JAK2 which is altered in CML and can be corrected by JAK2 inhibition.

Item Type:Conference Proceedings
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Copland, Professor Mhairi and Wheadon, Dr Helen and Rhodes, Dr Susan and Hopcroft, Dr Lisa
Authors: Rhodes, S., Copland, M., Hopcroft, L., Sayeski, P., and Wheadon, H.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Experimental Hematology
Publisher:Elsevier

University Staff: Request a correction | Enlighten Editors: Update this record